Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918381 · ClinicalTrials.gov registry record · NA
CellFX Treat & Resect Low-Risk BCC Feasibility Study
A NA study, sponsored by Pulse Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04918381 is a NA study that has completed, run by Pulse Biosciences. The registered enrollment target is 30 participants.
The verdict
NCT04918381, a NA study, has completed, sponsored by Pulse Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.
Interventions
- DEVICE CellFX System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-07-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04918381
The ClinicalTrials.gov registry entry for NCT04918381 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulse Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CellFX System is the first listed.
NCT04918381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04918381 about?
NCT04918381 is a clinical study titled "CellFX Treat & Resect Low-Risk BCC Feasibility Study". This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-tre...
What is the current status of trial NCT04918381?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-02. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT04918381?
The interventions under investigation include: CellFX System (DEVICE).
Who is sponsoring clinical trial NCT04918381?
This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.